FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Anicetti Vincent R (Last) (First) (Middle) COHERUS BIOSCIENCES, INC.					3. E	Issuer Name and Ticker or Trading Symbol Coherus BioSciences, Inc. [CHRS] Date of Earliest Transaction (Month/Day/Year) 11/14/2019									ationship of Reporting Person(s) to Issuer k all applicable) Director 10% Owner Officer (give title Other (specify below) below) Chief Operating Officer				vner
333 TWIN DOLPHIN DRIVE, SUITE 600 (Street) REDWOOD CITY CA 94065				4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)								Indiv ne) X	′					
(City)	(S		(Zip)	n Doris	rative	- So	riti	ios Ac	auirad	Dic	nocod (of or Bo	noficia	JIV 1	Ownor	1			
1. Title of Security (Instr. 3) 2. Trans Date		action 2 E Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			or 5. Amou Securiti Benefic Owned		int of es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock, \$0.0001 par value 11/14/2 Common Stock, \$0.0001 par value 11/14/2			11/14	/14/2019				M		2,500	A	\$2.50	005			D D			
			/2019	2019			S ⁽¹⁾		2,500	D	\$19.	26							
		T	able II -								osed of converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	n Date,	4. Transaction Code (Instr. 8)		5. Number of		6. Date Exercis. Expiration Date (Month/Day/Yea		е	7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		De Se	Price of rivative curity str. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly Owner Form Direct or Inc. (I) (In	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to	\$2.5005	11/14/2019			М			2,500	(2)	(06/30/2024	Common Stock	2,500		\$0.00	37,488	3	D	

Explanation of Responses:

Buy)

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
- $2. \ All \ of the \ shares \ underlying \ this \ option \ are \ vested \ and \ exercisable \ as \ of \ the \ date \ hereof.$

/s/ Jean Frederic Viret, as Attorney in Fact for Vincent R. 11/18/2019 **Anicetti**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.